b'COMMUNITY IN MOTIONGATES INSTITUTE GELSANA SHAPES CLINIMMUNE LEADSMARKS A DECADE WOUND CARE TRANSPLANTOF INNOVATION INNOVATION DIAGNOSTICS The Gates Biomanufacturing Facility In 2025, GelSana Therapeutics ClinImmune Labs continues tosupports cell therapy, biologics and reached a pivotal inflection point, strengthen its role as a national leader inprotein manufacturing to advance early- advancing its proprietary wound-care transplant immunology, with highlyphase clinical development. In 2025, the technology into late-stage development specialized diagnostic testing supportingGMP-compliant manufacturing hub and production. As a 2025 MedTech organ and stem cell transplantation.contributed to significant milestones, Innovator, the company is scaling Their precision lab services and clinicaldelivering CAR T-cell therapies and manufacturing capabilities and expertise advance patient-centered carepreparing for advanced manufacturing. accelerating wound care breakthroughs. and improve transplant outcomes. EXSERA DRIVES CUTTING-EDGE VITAN BIOTECHAUTOIMMUNE SURGICAL SKILLS ADVANCES CELL-DIAGNOSTICSAT CSI BASED DISCOVERYAs demand grows for deeper insight into A national leader in surgical education, Focused on unlocking the therapeuticimmune-driven diseases, Exsera the Center for Surgical Innovation potential of living cells, Vitan BiotechBioLabs is expanding its impact as a delivers over 400 hands-on training supports drug discovery throughtrusted resource for complex system courses each year and trains over 5,000 advanced cell-bassed assay platformstesting. Through highly specialized, FDA professionals from around the world, and biosensor technologies. By enablingGxP-compliant testing and collaboration, with immersive, multidisciplinary learning physiologically relevant testing, higher-they support biomarker translation and and connectivity to live operating rooms quality data is generated earlier,therapeutic development.and state-of-the-art facilities. strengthening translational impact.COMMUNITY Fitzsimons Innovation Community proudlyCELEBRATIONS welcomes Kenneth Ho as Chief Operating OfficerWith extensive experience in strategic finance and real-estate development, Kenneth brings expertise thatwill guide Fitzsimons through its next phase of2025 COLORADO BIOSCIENCE expansion and impact. His leadership ensures that RISING each new investmentwhether in infrastructure, Kenneth Hoinnovation or talentadvances the organizations Fitzsimons Innovation CommunitySTARChief Operating Officer AWARDmission to build a sustainable and connectedRUNNER-UPS community for discovery.9'